FIIs bought 60 lakh shares & PAT jumps over 250 per cent: Multibagger penny stock under Rs 5 hit upper circuit on December 03
The stock gave multibagger returns of 142 per cent from its 52-week low of Rs 1.55 per share.
On Tuesday, shares of Evexia Lifecare hit a 5 per cent upper circuit to Rs 3.76 per share from its previous closing of Rs 3.59 per share. The stock gave multibagger returns of 142 per cent from its 52-week low of Rs 1.55 per share.
Evexia Lifecare Limited formerly known as Kavit Industries Limited is engaged in the trading of chemicals, agricultural produce and various other products of consumer goods. The company has also formed a new subsidiary firm to set up pathology labs in Africa.
According to the financials, this FMCG company has a market cap of Rs 751 crore and reported positive numbers in its Quarterly Results (Q2FY25) and half-yearly results (H1FY25). In its quarterly results, the net sales increased by 155 per cent to Rs 26.71 crore and net profit increased by 250 per cent to Rs 0.69 crore in Q2FY25 compared to Q2FY24 while in its half-yearly results, the net sales increased by 92 per cent to Rs 47.13 crore and net profit increased by 255 per cent to Rs 0.96 crore in H1FY25 compared to H1FY24.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
Earlier, Evexia Lifecare Limited undertook significant strategic moves to bolster its pharmaceutical business. The company has allotted 24 crore convertible warrants to Raghuvir International Pvt Ltd and Shree Saibaba Exim Pvt Ltd, raising capital to fuel future growth. Additionally, Evexia has entered into a Term Sheet with DIPOned Research International Private Limited to acquire a 65% stake, aiming to expand its operations into drug discovery, development, and contract research services, thereby diversifying its portfolio and tapping into a new market
In September 2024, FIIs bought 60 lakh shares and increased their stake to 1.49 per cent compared to June 2024. Investors should keep an eye on this micro-cap stock under the radar.
Disclaimer: The article is for informational purposes only and not investment advice.